# Therapeutic Inertia in Lipid-Lowering Treatment: A Narrative Review

## TL;DR

Many high-risk patients don't get timely cholesterol-lowering treatment, leading to preventable heart problems and higher costs.

## Contribution

The paper introduces the concepts of clinician 'phenotypes' and 'avoidable atherosclerotic burden' to explain and address treatment delays.

## Key findings

- Fewer than one in three high-risk patients meet LDL-C targets, showing a gap between evidence and practice.
- Therapeutic inertia leads to avoidable vascular injury and increased cardiovascular events.
- Strategies like AI and structured lipid pathways can help shift care from reactive to proactive.

## Abstract

Therapeutic inertia in lipid-lowering treatment remains a striking paradox of modern cardiovascular medicine: at a time when the causal role of LDL-cholesterol in atherosclerotic disease is unequivocal and potent therapies are widely available, a substantial proportion of high- and very-high-risk patients still fail to receive timely treatment intensification. Contemporary European and international data consistently show fewer than one in three patients in secondary prevention achieve guideline-recommended LDL-C targets, revealing a persistent and unacceptable gap between scientific evidence and clinical reality. This narrative review examines therapeutic inertia as a key explanatory framework for this gap, describing its epidemiology, mechanisms, and clinical consequences in secondary cardiovascular prevention. We summarize the main physician-, patient-, and system-level determinants and propose recurrent clinician “phenotypes” of inertia that may help explain why opportunities are missed even in the highest-risk patients. The consequences are profound: therapeutic inertia contributes to what we propose as the conceptual framework of an “avoidable atherosclerotic burden”, the cumulative vascular injury that accrues each period in which LDL-C remains above target, translating into higher rates of avoidable cardiovascular events, and increased healthcare costs. Emerging strategies such as upfront combination therapy, decision-support systems, structured lipid pathways, and the integration of artificial intelligence offer practical tools to shift lipid management from reactive to proactive care. Overcoming therapeutic inertia is therefore not merely a matter of improving process metrics, but a clinical and ethical imperative. Closing the gap between evidence and practice requires transforming optimal lipid management from an exception into a system-level default, ensuring that every patient receives the full benefit of therapies proven to save lives. This work proposes a novel characterization of clinician ‘phenotypes’ and the concept of ‘avoidable atherosclerotic burden’ as a framework to understand and address this gap.